OBJECTIVES: To describe the patient characteristics, pharmacologic treatment patterns and costs among commercially insured patients diagnosed with aHCC. METHODS: Newly diagnosed aHCC adults were identified using the Truven MarketScan Research Databasesbetween 1/1/2008-9/30/2015 (ICD-9-CM 155.0.x, 155.2x; on ≥1 inpatient or ≥2 outpatient claims). Continuous enrollment was required 6 months prior- and 1 month post- first diagnosis (index date). A claim for systemic therapy after the index date was required. Patients with prior diagnosis of other primary/secondary cancers were excluded. Outcomes included a descriptive assessment of patient characteristics, patterns of systemic therapy use and monthly/total healthcare costs. RESULTS: